Table 2.

Tremelimumab antitumor activity FAS (n = 32).

Responsen% (95% CI)
Confirmed ORR618.8 (7.2–36.4)
Duration of responseNot reachedN/A
Time to response (median)99.5 days
Best objective response:
 Complete response26.3
 Partial response412.5
 Stable diseasea39.4
 Progressive disease (RECIST 1.1)2268.8
 Not evaluableb13.1
  • Abbreviations: CI, confidence interval; FAS, full analysis set; N/A, not applicable; ORR, objective response rate; RECIST 1.1, Response Evaluation Criteria In Solid Tumors, Version 1.1.

  • aStable disease for ≥15 weeks.

  • bIncomplete postbaseline assessments.